Search by keyword.
These innovative approaches encompass a diverse range of therapeutic strategies, including protein degraders, antibody-drug conjugates (ADCs), bioconjugates, macrocycles, covalent inhibitors, and oligonucleotide-based therapeutics (OLNs).
These modalities differ significantly from the traditional concepts of drug design, which often relied on small molecules designed according to Lipinski's ‘rule of five’. By challenging these traditional paradigms, new modalities open a range of possibilities that were not thought possible only a few years ago. These molecules tend to be of higher chemical complexity and target more complex biological pathways, requiring skilled scientists both for their design and synthesis.
Our world-class scientists push the boundaries of what can be made in the lab and tested, thereby removing practical hurdles, and giving medicinal chemists and designers the freedom to create the molecules they envision.
SpiroChem can provide your research with new modalities:
